Analysis of Review of Anti-tumor Drug Prescriptions Assisted by Information System
10.3870/j.issn.1004-0781.2024.01.008
- VernacularTitle:信息系统辅助抗肿瘤药物处方审核分析
- Author:
Kai CHENG
1
;
Huan WANG
;
Chunxiao DU
;
Xue MA
;
Lei SHANG
;
Zhiqiang HU
;
Tingting QI
Author Information
1. 四川省肿瘤医院·研究所、四川省癌症防治中心,电子科技大学附属肿瘤医院药学部,成都 610041
- Keywords:
Antitumor drug;
Information system;
Pre-review
- From:
Herald of Medicine
2024;43(1):47-53
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the problems of review of anti-tumor drug prescriptions and medical orders assisted by an information system to improve the review rules,and to provide a reference for improving review quality of anti-tumor drug prescription.Methods The problem with the pre-review of anti-tumor drug prescriptions and medical orders assisted by the information system in Sichuan Cancer Hospital during 2020-2022 were collected.The data came from the MEDICOM PASS system in Sichuan Cancer hospital.Clinical pharmacists made comments on relevant problems and analyzed the results.Results A total of 9 325 antitumor drug pre-approval problems,including 6 279 outpatient prescriptions(67.3%)and 3 046 inpatient orders(32.7%),among which 6 153(66.0%)were unsuitable indications,1 933(20.7%)were drug contraindications,449(4.8%)were problematic routes of administration,345(3.7%)were unsuitable drug compatibility,177(1.9%)were inappropriate drug frequency,133(1.4%)were problematic drug populations,74(0.8%)were unsuitable single doses,39(0.4%)were unacceptable drug interactions,22(0.2%)were unsuitable drug total.The results of clinical pharmacists'comments were 4 459 reasonable cases,with a false positive rate of 47.8%.The false positive problems included 2 264(50.8%)cases of unsuitable indications,1 933(43.3%)cases of drug contraindications,231(5.2%)cases of problematic routes of administration,and 31(0.7%)cases of unsuitable populations.Conclusion The review of anti-tumor drug prescriptions assisted by an information system can effectively intercept irrational drug use and improve the review quality of prescriptions and medical orders.However,the evidence-based medicine date of antitumor drugs is updated quickly.Pharmacists should constantly improve the prescription review rules based on the latest evidence-based medicine data.
